Article
Medicine, General & Internal
S. M. Olson, M. M. Newhams, N. B. Halasa, A. M. Price, J. A. Boom, L. C. Sahni, P. S. Pannaraj, K. Irby, T. C. Walker, S. P. Schwartz, A. B. Maddux, E. H. Mack, T. T. Bradford, J. E. Schuster, R. A. Nofziger, M. A. Cameron, K. Chiotos, M. L. Cullimore, S. J. Gertz, E. R. Levy, M. Kong, N. Z. Cvijanovich, M. A. Staat, S. Kamidani, B. M. Chatani, S. S. Bhumbra, K. E. Bline, M. G. Gaspers, C. Hobbs, S. M. Heidemann, M. Maamari, H. R. Flori, J. R. Hume, M. S. Zinter, K. N. Michelson, L. D. Zambrano, A. P. Campbell, M. M. Patel, G. Randolph
Summary: The study examined the effectiveness of the BNT162B2 vaccine in preventing hospitalization and ICU admission in adolescents. The results demonstrated that full vaccination significantly reduced the risk of hospitalization and ICU admission.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Biochemistry & Molecular Biology
Noa Dagan, Noam Barda, Tal Biron-Shental, Maya Makov-Assif, Calanit Key, Isaac S. Kohane, Miguel A. Hernan, Marc Lipsitch, Sonia Hernandez-Diaz, Ben Y. Reis, Ran D. Balicer
Summary: The BNT162b2 COVID-19 vaccine showed high effectiveness in pregnant women in an observational cohort study in Israel, similar to the effectiveness seen in the general population.
Letter
Medicine, General & Internal
Shmuel Benenson, Yonatan Oster, Matan J. Cohen, Ran Nir-Paz
Summary: A systematic vaccination program for healthcare workers at Hadassah Medical Center in Israel showed high effectiveness in preventing Covid-19 starting from the second week after the first dose of BNT162b2 vaccine.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
Jie Wei, Weiya Zhang, Michael Doherty, Zachary S. Wallace, Jeffrey A. Sparks, Na Lu, Xiaoxiao Li, Chao Zeng, Guanghua Lei, Yuqing Zhang
Summary: In a population-based study in the UK, the BNT162b2 vaccine showed higher efficacy than the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection and hospitalization for COVID-19, but there was no significant difference in the risk of death from COVID-19.
Article
Multidisciplinary Sciences
Tal Patalon, Yaki Saciuk, Asaf Peretz, Galit Perez, Yoav Lurie, Yasmin Maor, Sivan Gazit
Summary: In this retrospective study, the authors demonstrate a significant waning of mRNA vaccine effectiveness against the Omicron variant of SARS-CoV-2 infection within a few months after administration of the third dose of the BioNTech/Pfizer BNT162b2 vaccine.
NATURE COMMUNICATIONS
(2022)
Article
Medicine, General & Internal
D. Mevorach, E. Anis, N. Cedar, M. Bromberg, E. J. Haas, E. Nadir, S. Olsha-Castell, D. Arad, T. Hasin, N. Levi, R. Asleh, O. Amir, K. Meir, D. Cohen, R. Dichtiar, D. Novick, Y. Hershkovitz, R. Dagan, I Leitersdorf, R. Ben-Ami, I Miskin, W. Saliba, K. Muhsen, Y. Levi, M. S. Green, L. Keinan-Boker, S. Alroy-Preis
Summary: The incidence of myocarditis increased after receiving the BNT162b2 vaccine in Israel, particularly after the second dose among young male recipients. The clinical presentation of myocarditis after vaccination was usually mild.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Letter
Medicine, General & Internal
Thomas Rohban
Summary: In a real-world data analysis, researchers found that adults aged 50 or above who received a booster shot of the Pfizer-BioNTech vaccine at least 5 months after their second dose had 90% lower mortality due to Covid-19 compared to those who did not receive a booster. The study suggests that reports on all-cause mortality would have been helpful in improving our understanding of the booster effect.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Medicine, General & Internal
Yinon M. Bar-On, Yair Goldberg, Micha Mandel, Omri Bodenheimer, Laurence Freedman, Sharon Alroy-Preis, Nachman Ash, Amit Huppert, Ron Milo
Summary: The study shows that receiving a booster dose of the BNT162b2 vaccine can significantly lower the rates of confirmed Covid-19 and severe illness, as well as reduce mortality among individuals aged 60 and above.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
Lorenzo Azzi, Daniela Dalla Gasperina, Giovanni Veronesi, Mariam Shallak, Vittorio Maurino, Andreina Baj, Francesco Gianfagna, Pierpaolo Cavallo, Francesco Dentali, Lucia Tettamanti, Fabrizio Maggi, Lorenzo Stefano Maffioli, Angelo Tagliabue, Roberto Sergio Accolla, Greta Forlani
Summary: Limited studies have been conducted on the development of mucosal immune response after BNT162b2-booster vaccination. Serum and saliva samples were collected from 50 healthcare workers before and after the booster dose. The results showed that the booster dose elicited a stronger systemic immune response but failed to activate effective mucosal immunity against the Omicron BA.1 variant.
Article
Biology
Vincenza Granata, Roberta Fusco, Sergio Venanzio Setola, Roberta Galdiero, Carmine Picone, Francesco Izzo, Roberta D'Aniello, Vittorio Miele, Roberta Grassi, Roberto Grassi, Antonella Petrillo
Summary: In this study, ultrasound findings of lymphadenopathy after BNT162b2 Pfizer vaccine were assessed, revealing various features such as eccentric cortical thickening, wide echogenic hilum, oval shape, and asymmetry. The most common presentation was eccentric cortical thickening with wide echogenic hilum and oval shape.
Article
Medicine, General & Internal
Ronen Arbel, Ariel Hammerman, Ruslan Sergienko, Michael Friger, Alon Peretz, Doron Netzer, Shlomit Yaron
Summary: Among 843,208 participants in Israel aged 50 years or older who had received two doses of the BNT162b2 vaccine at least 5 months earlier, those who received a booster had 90% lower mortality due to Covid-19 than those who did not receive a booster during the 54-day study period.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Review
Pharmacology & Pharmacy
Yvette N. Lamb
Summary: BNT162b2, a lipid nanoparticle-formulated mRNA vaccine encoding the SARS-CoV-2 spike protein, has received emergency use authorization in multiple countries for individuals aged 16 and older to prevent COVID-19.
Article
Medicine, General & Internal
Yinon M. Bar-On, Yair Goldberg, Micha Mandel, Omri Bodenheimer, Laurence Freedman, Nir Kalkstein, Barak Mizrahi, Sharon Alroy-Preis, Nachman Ash, Ron Milo, Amit Huppert
Summary: After receiving a third dose of the BNT162b2 mRNA vaccine, Israeli residents aged 60 and above who had previously received two doses of the vaccine saw significantly lower rates of confirmed Covid-19 infection and severe illness compared to those who did not receive a booster shot, indicating the effectiveness of the booster dose in reducing infection and severe illness.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Immunology
Hamad Ali, Abdulmohsen Alterki, Sardar Sindhu, Barrak Alahmad, Maha Hammad, Salman Al-Sabah, Mohammad Alghounaim, Mohammad H. Jamal, Ali Aldei, Mohammad J. Mairza, Maitham Husain, Sriraman Deverajan, Rasheed Ahmad, Preethi Cherian, Irina Alkhairi, Abdullah Alkandari, Jehad Abubaker, Mohamed Abu-Farha, Fahd Al-Mulla
Summary: Individuals with type-2 diabetes mellitus had lower levels of SARS-CoV-2 IgG and neutralizing antibodies after receiving the COVID-19 vaccine, suggesting a slightly reduced immune response compared to non-diabetic individuals. However, both diabetic and non-diabetic individuals showed robust immune responses to the vaccine. Continuous monitoring of antibody levels may help guide the need for booster shots, especially for individuals with diabetes.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Immunology
Eun-Ju Kim, Seok-Ju Yoo
Summary: Cases of pulmonary embolism and deep vein thrombosis have been reported after mRNA COVID-19 vaccine (BNT162b2) administration, although the association with mRNA vaccines has not been proven, reliable studies have confirmed the link with thrombosis with thrombocytopenia syndrome (TTS), particularly for viral vector vaccines.
Article
Pediatrics
Judah Freedman, Eugene Leibovitz, Ruslan Sergienko, Amalia Levy
Summary: This study found that Bedouin children from low-income areas had a higher risk of PICU hospitalization after infectious diseases compared to Jewish children. Maternal multiparity, low birth weight, and younger age were identified as significant risk factors for PICU hospitalizations with infectious diseases.
PEDIATRICS AND NEONATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Shirley Regev, Doron Schwartz, Orly Sarid, Ganit Goren, Vered Slonim-Nevo, Michael Friger, Ruslan Sergienko, Dan Greenberg, Alon Monsonego, Anna Nemirovsky, Shmuel Odes
Summary: This study aimed to investigate the effectiveness of a CD-tailored cognitive-behavioral and mindfulness intervention (COBMINDEX) in reducing abdominal pain and fatigue in patients with CD, as well as the mediating role of changes in abdominal pain and fatigue on improvements in work productivity and daily activities. The results showed that the intervention group receiving COBMINDEX had significantly lower levels of abdominal pain, fatigue, and impairments in work and daily activities compared to the control group. Furthermore, changes in abdominal pain and fatigue mediated the beneficial effects of COBMINDEX on work productivity and daily activities.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Article
Endocrinology & Metabolism
Joseph Azuri, Ariel Hammerman, Enis Aboalhasan, Ben Sluckis, Ronen Arbel
Summary: This study aimed to compare the cost-effectiveness of two drugs, tirzepatide and semaglutide, for weight reduction in patients with type 2 diabetes. The results showed that tirzepatide (15mg) was more effective in reducing weight compared to semaglutide (2.4mg), and it also had a lower cost of treatment.
DIABETES OBESITY & METABOLISM
(2023)
Article
Obstetrics & Gynecology
Tamar Wainstock, Ruslan Sergienko, Shani Orenshtein, Eyal Sheiner
Summary: This retrospective cohort study aimed to identify maternal background, medical and gynecological characteristics associated with COVID-19 vaccination likelihood among pregnant women. The study found that younger age, lower socioeconomic score, being Bedouin Arab, poor obstetric history, recurrent pregnancy loss, and insufficient prenatal care were associated with lower vaccination rates. The study also observed differences in risk factors between different ethnicities.
INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS
(2023)
Article
Cardiac & Cardiovascular Systems
Hilmi Alnsasra, Gal Tsaban, Adam Solomon, Fouad Khalil, Enis Aboalhasan, Jean Marc Weinstein, Joseph Azuri, Ariel Hammerman, Ronen Arbel
Summary: Comparing dapagliflozin and empagliflozin for the prevention of cardiovascular death in patients with heart failure, the study found that dapagliflozin provides better monetary value across the spectrum of ejection fraction.
AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS
(2023)
Article
Infectious Diseases
Roy Zucker, Gil Lavie, Yael Wolff-Sagy, Noa Gur-Arieh, Hila Markovits, Wiessam Abu-Ahmad, Erez Battat, Noga Ramot, Tanya Beckenstein, Guy Carmeli, Avner Mark-Amir, Gal Wagner-Kolasko, Amos Edry, Hadar Duskin-Bitan, Shlomit Yaron, Alon Peretz, Ariel Hammerman, Doron Netzer, Ronen Arbel
Summary: The objective of this study was to identify the characteristics of individuals at the highest risk for mpox in order to establish evidence-based vaccine prioritization criteria. The study found that individuals born in 1980 or later, with a history of syphilis, registered in primary healthcare clinics in the Tel Aviv district, using HIV pre-exposure prophylaxis medication, using PDE5 inhibitors, and with recent sexually transmitted infections were at higher risk for mpox. These risk factors can assist in the equitable allocation of vaccines in future outbreaks.
CLINICAL MICROBIOLOGY AND INFECTION
(2023)
Article
Cardiac & Cardiovascular Systems
Ramesh Nadarajah, Jianhua Wu, David Hogg, Keerthenan Raveendra, Yoko M. Nakao, Kazuhiro Nakao, Ronen Arbel, Moti Haim, Doron Zahger, John Parry, Chris Bates, Campbel Cowan, Chris P. Gale
Summary: A machine learning algorithm called FIND-AF was developed to predict the risk of incident atrial fibrillation (AF) within 6 months using primary care data. The algorithm outperformed existing scores in predicting AF and can be applied at scale in routine practice.
Article
Endocrinology & Metabolism
Joseph Azuri, Ariel Hammerman, Enis Aboalhasan, Ben Sluckis, Ronen Arbel
Summary: Comparative analysis shows that semaglutide has better value for money than liraglutide in terms of weight reduction.
Article
Oncology
Oded Icht, Avi Leader, Erez Batat, Lilach Yosef, Tzippy Shochat, Daniel A. Goldstein, Elizabeth Dudnik, Galia Spectre, Pia Raanani, Ariel Hammerman, Alona Zer
Summary: This study found that patients with ALK-positive NSCLC have a higher risk of VTE, but no significant difference in ATE risk. Prospective studies are needed to evaluate thromboprophylaxis in ALK-positive NSCLC.
Letter
Medicine, General & Internal
Ronen Arbel, Ariel Hammerman, Doron Netzer
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Meeting Abstract
Obstetrics & Gynecology
Tamar Wainstock, Ruslan Sergienko, Eyal Sheiner
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
(2023)
Letter
Medicine, General & Internal
Tracy B. Hoeg, Ram Duriseti, Vinay Prasad
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Oncology
Oded Icht, Avi Leader, Erez Batat, Lilach Yosef, Tzippy Shochat, Daniel A. Goldstein, Elizabeth Dudnik, Galia Spectre, Pia Raanani, Ariel Hammerman, Alona Zer
Summary: This study found that patients with ALK-positive NSCLC had a higher risk of VTE compared to those without ALK rearrangement, but there was no association between ALK positivity and ATE incidence.
Article
Obstetrics & Gynecology
P. Schwarzman, E. Sheiner, R. Sergienko, R. Kessous
Summary: Objective mode of delivery, specifically cesarean section, is associated with an increased future risk for neoplasms, including uterine cancer. This population-based cohort analysis found a significantly higher incidence of benign and malignant neoplasms in patients who underwent cesarean section compared to vaginal delivery. However, no significant association was found with breast and ovarian malignancies.
ARCHIVES OF GYNECOLOGY AND OBSTETRICS
(2023)